Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Risk of AML with etoposide and teniposide reviewed

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Risk of AML with etoposide and teniposide reviewed. React. Wkly. 513, 3 (1994). https://doi.org/10.2165/00128415-199405130-00007

    Download citation

    Keywords

    • Acute Myeloid Leukemia
    • Germ Cell
    • Etoposide
    • Myeloid Leukaemia
    • Cumulative Dose